Premium
A plant‐derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry
Author(s) -
Bose Mihika,
Kamra Mohini,
Mullick Ranajoy,
Bhattacharya Santanu,
Das Saumitra,
Karande Anjali A.
Publication year - 2017
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1002/1873-3468.12629
Subject(s) - hepatitis c virus , virology , viral entry , entry inhibitor , in vivo , cytotoxicity , in vitro , drug , virus , ex vivo , chemistry , biology , pharmacology , viral replication , biochemistry , microbiology and biotechnology
Emergence of drug‐resistant viruses, high cost and adverse side‐effects associated with the standard therapy against hepatitis C virus (HCV) infection demonstrate the need for development of well tolerated and effective antivirals. We identified and chemically characterised the dehydrorotenoid boeravinone H, isolated from the herb Boerhavia diffusa , as a new inhibitor of HCV entry. The compound significantly inhibits the binding and entry of hepatitis C‐like particles (HCV‐LPs) in hepatoma cells in vitro with no apparent cytotoxicity. Boeravinone H inhibits the initial phase of HCV entry probably by acting directly on the viral particle. Importantly, the compound prevents HCV entry and infection in cell culture ( ex vivo ). Thus, boeravinone H is a potential antiviral agent for the prevention and control of HCV infection.